This study, published in the Journal of Nuclear Medicine, demonstrates that the early phase (first 5–10 minutes) of a dynamic [$^{18}$F]MK6240 tau PET scan can serve as a reliable surrogate for cerebral perfusion. By extracting this "free" blood-flow information, researchers can simultaneously assess both tau pathology and neurodegeneration in a single imaging session, streamlining the diagnostic process for Alzheimer’s disease.
TL;DR
The early signal from [$^{18}$F]MK6240 PET scans provides a robust index of cerebral perfusion that correlates highly with established amyloid-based perfusion measures. This allows a single PET tracer to provide a "two-for-one" biomarker, capturing both specific tau pathology and general neurodegenerative changes.
What Problem Does This Paper Address?
In the study of Alzheimer’s disease (AD), clinicians use the A/T/N framework: Amyloid, Tau, and Neurodegeneration. While PET scans are excellent for "A" and "T," measuring "N" (often via cerebral blood flow or perfusion) usually requires a separate scan, such as [$^{15}$O]H$_2$O PET or arterial spin labeling (ASL) MRI.
These additional scans increase costs, radiation exposure, and patient burden. Researchers have previously shown that the early "wash-in" phase of amyloid tracers can proxy for blood flow. This paper investigates whether [$^{18}$F]MK6240—a high-affinity second-generation tau tracer—can do the same, effectively turning a standard tau scan into a multi-modal diagnostic tool.
Methods
The researchers analyzed 49 subjects: 25 cognitively normal (CN), 17 with mild cognitive impairment (MCI), and 7 with AD.
- Imaging: All subjects underwent dynamic [$^{18}$F]MK6240 (tau) and [$^{11}$C]PiB (amyloid) PET scans, plus structural MRI.
- Modeling:
- Invasive Gold Standard: In 24 subjects, arterial blood was sampled to create a metabolite-corrected input function. They used a 1-tissue-compartment model (1T2kv) to estimate $K_1$ (the rate of tracer transfer from plasma to brain).
- Non-invasive Proxy: They used the Simplified Reference Tissue Model 2 (SRTM2) to calculate $R_1$, the relative delivery rate of the tracer compared to a reference region (the cerebellum).
- Simulations: They performed computer simulations to ensure that the "stickiness" of the tracer (specific binding to tau) didn't bias the perfusion measurements during the first few minutes of the scan.
- Validation: They compared the MK6240-derived $R_1$ values against $R_1$ values from [$^{11}$C]PiB, which is already an established surrogate for perfusion.
Datasets
The study utilized a primary clinical dataset of 49 human subjects recruited through Massachusetts General Hospital. This included:
- CN (Cognitively Normal): 25 subjects.
- MCI (Mild Cognitive Impairment): 17 subjects.
- AD (Alzheimer’s Disease): 7 subjects.
- Sub-cohort: 24 subjects provided arterial blood samples for kinetic modeling validation.
Key Insights and Ideas
- The "Wash-in" Window: Perfusion information is most accurate in the first 5 minutes. Simulations showed that while specific binding to tau increases over time, its influence on the $K_1$ and $R_1$ estimates remains under 2% if only the first 5 minutes of data are used.
- High Extraction Fraction: [$^{18}$F]MK6240 appears to have a higher extraction fraction (the percentage of tracer that crosses into the brain on the first pass) than amyloid tracers like PiB. This potentially makes it a more sensitive tool for detecting subtle changes in blood flow.
- Regional Sensitivity: The study found that perfusion deficits were most prominent in the temporal and parietal cortices of AD patients—regions known to be heavily affected by neurodegeneration.
Key Results
- Internal Consistency: Non-invasive $R_1$ estimates (SRTM2) agreed almost perfectly with blood-based $R_1$ calculations ($r = 0.99$; mean difference $0.024 \pm 0.027$).
- Head-to-Head Validation: $R_1$ measurements from [$^{18}$F]MK6240 correlated strongly with those from [$^{11}$C]PiB ($r = 0.93$; mean difference $-0.001 \pm 0.068$).
- Clinical Differentiation: Statistically significant differences in regional $R_1$ were observed between CN, MCI, and AD groups, particularly in the temporal and parietal cortices, mirroring the expected patterns of hypoperfusion in AD.
- Stability: Perfusion indices remained stable whether 5 or 10 minutes of data were used, though 5 minutes minimized bias from specific binding.
Limitations and Future Work
- Sample Size: The AD group was relatively small ($n=7$), which may limit the statistical power for some regional comparisons.
- Scanner Variability: Data were collected on two different PET systems (ECAT EXACT HR+ and Discovery MI). While the authors calibrated the systems, this is a common real-world source of noise.
- Missing "True" Gold Standard: While PiB is a good proxy, the authors note that a direct head-to-head comparison with [$^{15}$O]H$_2$O PET (the absolute gold standard for blood flow) is still needed to precisely determine the extraction fraction of MK6240.
- Future Direction: This method opens the door for "dual-phase" imaging protocols where a single injection provides a perfusion map (early phase) and a tau pathology map (late phase).
Summary updated